---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-257381"
form_type: "8-K"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:21:05.418247+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Indivior Q3 net revenue $314M (+2% YoY); raises FY2025 guidance materially

## Summary
- SUBLOCADE net revenue $219M (+15% YoY); U.S. SUBLOCADE up 14% to $203M.
- Adjusted EBITDA $120M (+14% YoY); non-GAAP diluted EPS $0.72 vs $0.49 YoY.
- FY2025 net revenue guidance raised to $1.18-1.22B; adjusted EBITDA now $400-420M.
- Plans to exit several ROW markets, discontinue OPVEE sales support, saving at least $150M annually from 2026.
- Cash and investments $473M at Q3 end, up $125M from year-end 2024.

## SEC filing metadata
- accession: 0001193125-25-257381
- form_type: 8-K
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000119312525257381/0001193125-25-257381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000119312525257381/d58033d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-257381
- JSON: https://secwatch.observer/filing/0001193125-25-257381.json
- Plain text: https://secwatch.observer/filing/0001193125-25-257381.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.